Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

AGO Score for Complete Secondary Cytoreduction (DESKTOP III)

This route interprets the operational AGO criteria used to select the DESKTOP III trial population: ECOG performance status 0, ascites strictly below 500 mL, and complete gross resection at initial surgery.

Evidence-based context for fast calculator use

Purpose:
Neutral interpreter of the three operational AGO criteria used in DESKTOP III, supported by DESKTOP II, for first platinum-sensitive recurrence of epithelial ovarian cancer.
Population:
patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment
Factors:
ECOG performance status at recurrence, Ascites at recurrence, Residual status after initial surgery
HomeAGO Score for Complete Secondary Cytoreduction (DESKTOP III)
Pin your most used calculators here by clicking the star in the dropdown.

AGO Score for Complete Secondary Cytoreduction (DESKTOP III)

Use only for first platinum-sensitive recurrence of epithelial ovarian cancer before recurrence treatment or contemplated secondary cytoreduction. Only ECOG 0 meets this AGO criterion.

mL

Enter the raw volume. The criterion is strictly below 500 mL; exactly 500 mL does not qualify.

Clinical Context & Background

This route interprets the operational AGO criteria used to select the DESKTOP III trial population: ECOG performance status 0, ascites strictly below 500 mL, and complete gross resection at initial surgery. DESKTOP II prospectively supported the criteria before the randomized DESKTOP III trial.
Use only for an adult with first, established histologic or clinical/radiologic recurrence of epithelial ovarian cancer, a platinum-free interval of at least 6 months after completion of initial platinum treatment, and assessment before recurrence treatment or contemplated secondary cytoreduction. The route excludes CA125-only recurrence, later recurrence, platinum-refractory or early relapse, interval debulking, post-recurrence-treatment assessment, non-epithelial or borderline disease, and unknown source facts.
The result reports whether the three historical trial-defined criteria match. It does not calculate an individualized complete-resection probability, survival, operative eligibility, treatment benefit, futility, or a treatment recommendation. AGO-negative is not a universal exclusion. iMODEL is a separate six-factor model and is not combined with this result.
Formula Logic
After applicability validation: AGO-positive only when ECOG = 0 AND raw ascites < 500 mL AND initial surgery achieved complete gross resection.

Reference Data

Source resultExact operational ruleSafe interpretation
AGO-positiveAll 3 criteria presentTrial-defined criteria match only
AGO-negativeAt least 1 criterion absentDoes not universally exclude complete resection

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use AGO Score for Complete Secondary Cytoreduction (DESKTOP III) when neutral interpreter of the three operational AGO criteria used in DESKTOP III, supported by DESKTOP II, for first platinum-sensitive recurrence of epithelial ovarian cancer.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning AGO-positive through AGO-negative.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm organ site, pathology, menopausal or postoperative context, imaging, biomarker assay, and specialist referral pathway.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Adnexal-mass, cervical postoperative, endometrial, and ovarian cytoreduction models answer different clinical questions.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment

How to apply this result

For a representative case, verify ECOG performance status at recurrence, Ascites at recurrence, Residual status after initial surgery, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Gynecologic Oncology hubContinue to related calculators and clinical workflow resources.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed AGO cases passed through visible production controls, including AGO-positive, the exact 500 mL negative threshold, and the incomplete-assessment path.
    • No unexpected N/A, literal undefined value, stale control, unsupported risk gauge, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/ago-ovarian-cancer-score-2026-08-03.json.

  2. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 12 visible submissions.
    • Overall browser status: failed-console. medium: Production emitted minified React error #418 during route load.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/ago-ovarian-cancer-score.json.

  3. : Input workflow simplified and revalidated

    • Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
    • Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
    • Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.

  4. : Model lock corrected

    • Locked the route to the operational three-factor AGO criteria used in DESKTOP III and supported by DESKTOP II.
    • Kept Tian iMODEL separate and disclosed the strict ascites below 500 mL implementation boundary.

  5. : Raw and applicability inputs corrected

    • Replaced favorable pre-binned defaults with raw ECOG, ascites volume, initial residual status, and enforceable first-recurrence, platinum-free, recurrence-evidence, timing, prior-treatment, disease, and surgical-context fields.
    • Added exact malformed, incomplete, and outside-scope states without producing a false positive or negative.

  6. : Ascites boundary and treatment language corrected

    • Implemented raw ascites strictly below 500 mL, so 499.999 mL meets and 500 mL does not meet the operational criterion.
    • Removed individualized probabilities, candidate labeling, surgery recommendations, systemic-therapy preference, benefit, futility, and survival claims.

  7. : Full validation completed

    • 1024/1024 independent deterministic assertions passed across model identity, the applicable matrix, exact boundaries, malformed and applicability cases, trace, UI/reset/serialization, immutability, registry, report, and no-panel checks.
    • This is software implementation verification against the locked public definitions, not prospective or independent clinical validation.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

Tian iMODEL for Ovarian Cancer RecurrenceROMA Score (Ovarian)RMI (Risk of Malignancy Index)

Frequently Asked Questions

What makes the operational DESKTOP III AGO criteria positive?

After source-population applicability is confirmed, all three must be present: ECOG 0, raw ascites strictly below 500 mL, and complete gross resection at the initial operation. A value of exactly 500 mL does not meet this implementation lock.

Does an AGO-negative result rule out complete secondary cytoreduction?

No. It means one or more trial selection criteria are absent. It is not a universal exclusion, individualized probability, operative judgment, or treatment recommendation.

Is this the same as iMODEL?

No. AGO/DESKTOP uses three binary operational criteria. Tian iMODEL is a separate six-factor weighted model used in a different evidence pathway. This calculator does not combine them.

Evidence-based oncology decision support. Verify with clinical guidelines.